II
Thanks for raising this, I had thought Bisantrene's description as a ''Topo-II inhibitor with anthracycline-like activity" in this paper as unusual, or maybe straight up misleading given the drug's history, more recent discoveries, and Race's own description of the drug. The reason for this may not come to light but it certainly makes you wonder if there was any agenda/intent behind this?
II Thanks for raising this, I had thought Bisantrene's...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |